ImmunityBio Faces Class Action Over Anktiva Claims; Investors Have Until May 26

ImmunityBio, Inc. ($IBRX) is facing a significant class action lawsuit alleging the company made false and misleading statements about Anktiva and its business operations, with investors who suffered losses during a critical two-month window now required to act before a May 26, 2026 deadline. The lawsuit, filed in the U.S. District Court for the Central District of California, centers on representations made during a narrow but consequential class period from January 19, 2026 through March 24, 2026—a timeframe that captures what appears to be a material shift in investor perception regarding the company's flagship immunotherapy asset.

The Legal Action and Timeline

Bragar Eagel & Squire, P.C., a law firm specializing in securities litigation, is urging ImmunityBio shareholders who experienced significant losses to contact the firm regarding their legal rights. The lawsuit represents a critical moment for affected investors, as the deadline to apply for lead plaintiff status expires on May 26, 2026.

The class action alleges that defendants—presumably including company leadership and possibly board members—disseminated materially false and misleading information during the specified class period. Key elements of the litigation include:

• Alleged misrepresentations regarding Anktiva's capabilities and efficacy
• False statements concerning the company's broader business operations
• Class period: January 19, 2026 – March 24, 2026 (approximately 65 days)
• Jurisdiction: U.S. District Court for the Central District of California
• Lead plaintiff deadline: May 26, 2026

The timing of this class period is particularly noteworthy, as it suggests a compressed window during which market sentiment shifted dramatically regarding ImmunityBio's core asset or operational prospects.

Market Context and Sector Backdrop

ImmunityBio operates within the highly competitive and heavily scrutinized biopharmaceutical sector, where regulatory approval, clinical trial data, and product efficacy claims are subject to intense investor and regulatory scrutiny. The company's focus on Anktiva positions it within the immunotherapy space, an area that has attracted substantial capital but also witnessed significant volatility as clinical results and commercialization prospects shift.

The biotech sector has experienced heightened litigation activity in recent years, with securities class actions increasingly targeting companies where clinical trial results, FDA communications, or commercial guidance diverge materially from prior representations. The allegation of false statements regarding a drug's "capabilities" suggests potential issues related to:

• Clinical efficacy claims that may have been overstated or unsubstantiated
• Regulatory pathway assumptions that proved incorrect
• Commercial viability assessments that lacked adequate foundation
• Competitive positioning statements that mischaracterized Anktiva's market advantages

For a company in the immunotherapy space, where investors often value pipeline potential significantly, misrepresentations about a lead asset can trigger severe equity value destruction. The concentrated 65-day class period suggests a discrete triggering event—potentially an adverse clinical update, FDA communication, or competitive announcement—that prompted the lawsuit.

Investor Implications and Market Significance

This litigation carries substantial implications for $IBRX shareholders and the broader biopharmaceutical investment landscape:

For Affected Shareholders: Investors who purchased ImmunityBio securities during the January 19 – March 24 window and experienced losses have a narrow window to assert their rights. The requirement to apply for lead plaintiff status by May 26 means affected investors must act quickly, as failure to do so may limit their participation in any potential settlement or judgment recovery.

For Market Participants: The lawsuit underscores the risks inherent in biotech investments, particularly when company guidance regarding clinical assets diverges materially from underlying reality. Investors in similar immunotherapy-focused companies should carefully review management statements regarding drug efficacy, regulatory interactions, and commercialization assumptions.

For ImmunityBio: Beyond immediate legal exposure, the litigation threatens to undermine investor confidence in management's credibility and governance. Class action settlements in the biotech sector can reach substantial sums, and reputational damage often compounds the financial impact. The company faces questions about whether internal controls and disclosure procedures adequately protected investors.

Precedent and Regulatory Climate: Securities litigation against biotech companies has become increasingly common as regulators and plaintiff attorneys focus on pharmaceutical company disclosure practices. This case may influence how other companies in the immunotherapy space communicate about clinical candidates and commercial prospects.

Looking Forward

As ImmunityBio navigates this legal challenge, investors should monitor developments closely. The May 26, 2026 lead plaintiff deadline represents a critical juncture, but the litigation itself may extend over months or years as discovery proceeds and the case develops. Settlement discussions could emerge, or litigation could proceed to trial, with each outcome carrying different implications for shareholders.

The lawsuit serves as a stark reminder of the disclosure obligations facing publicly-traded biopharmaceutical companies and the substantial consequences when investor-facing statements diverge from underlying business realities. For investors holding $IBRX or considering positions in similar biotech companies, this case reinforces the importance of rigorous due diligence, skepticism toward bullish management guidance lacking substantive support, and careful monitoring of regulatory communications and clinical data.

Affected investors should consult with legal counsel regarding their potential claims and deadlines, while current and prospective shareholders should assess how this litigation affects their view of ImmunityBio's governance, management credibility, and long-term business prospects.